Research programme: anti-infectives - Oscient Pharmaceuticals

Drug Profile

Research programme: anti-infectives - Oscient Pharmaceuticals

Alternative Names: GTC 162 series; GTC 637 series

Latest Information Update: 17 Jan 2011

Price : $50

At a glance

  • Originator Oscient Pharmaceuticals
  • Class
  • Mechanism of Action Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Respiratory tract infections

Most Recent Events

  • 25 Oct 2007 This programme is still in active development
  • 29 Sep 2005 Oscient's oral PDF inhibitors research programme is available for licensing (
  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top